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Objectives: Although the chemokine CXCL12 and its receptor CXCR4 have been implicated in metastasis of
non–small cell lung carcinoma, the prognostic significance of these molecules is poorly defined. This study aimed
to determine whether expression of these molecules is associated with clinicopathologic features and disease-free
survival in non–small cell lung carcinoma.
Methods: Immunohistochemical staining for CXCL12 and CXCR4 was performed on 154 primary non–small
cell lung carcinomas. Staining intensity was compared with tumor histotype, TNM stage, and disease-free sur-
vival; correlation was assessed by using the Fisher’s exact test, and Kaplan–Meier and Cox multivariate propor-
tional hazards regression analysis.
Results: Intense CXCL12 immunostaining was associated with nodal metastasis, although no difference in sur-
vival was observed. The prognostic relevance of CXCR4 was dependent on its subcellular location: in univariate
analysis intense nuclear staining was significantly associated with lower T classification and improved disease-
free survival in patients with adenocarcinoma, whereas cytomembranous staining was associated with distant
metastasis and decreased disease-free survival. On multivariate analysis, cytomembranous CXCR4 expression
conferred a significantly worse disease-free survival (relative risk, 2.8; 95% confidence interval, 1.4–5.7;
P ¼ .004).
Conclusions: Cytomembranous expression of the chemokine receptor CXCR4 in adenocarcinoma of the lung is
an independent risk factor associated with worse disease-free survival, whereas nuclear staining confers a survival
benefit. These findings are consistent with a model in which CXCR4 promotes tumor cell proliferation and me-
tastasis when present in the cytoplasm or cell membrane, whereas localization of this molecule in the nucleus pre-
vents it from exerting these effects.
Wagner et al General Thoracic SurgeryChemokine receptors constitute a family of 7-transmem-
brane proteins that interact specifically with chemokines,
a subset of cytokines known for their role in cell movement
along a chemical gradient (chemotaxis). On exposure to
their specific chemokine ligands, the receptors are internal-
ized within endosomes and participate in signal transduc-
tion, culminating in cytoskeletal rearrangement and
directional migration toward the chemokine source. This
process is vital in many physiologic events, including migra-
tion of precursor cells during development and homing of
leukocytes to injured or infected tissues. In addition to their
involvement in physiologic processes, these molecules play
an increasingly understood role in the progression of a large
number of human malignancies by stimulating the prolifer-
ation, invasion, and metastasis of tumor cells.1-3
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shown to express the chemokine receptor CXCR4. These
cells undergo increased proliferation, chemotaxis, and metas-
tasis in vitro and in murine models in response to CXCL12,
the specific chemokine ligand for CXCR4.3 In the lung
CXCL12 is produced by pulmonary epithelial cells and nor-
mally functions to recruit leukocytes to the airspaces during
acute lung injury.4 Because malignant lung tissue has the ca-
pacity to express both CXCL12 and its receptor, CXCR4, it is
hypothesized that these molecules could drive tumor progres-
sion by means of autocrine or paracrine mechanisms. How-
ever, although experiments in murine models have yielded
results consistent with this model, the clinical relevance of
chemokine receptor expression in lung cancer and other com-
mon epithelial malignancies remains uncertain.
The aim of this study was to quantitate the expression
of CXCL12 and CXCR4 in a series of primary NSCLCs
and to determine whether these molecules are associated
with clinicopathologic features of NSCLC, including tumor




We retrospectively selected 154 primary NSCLCs from 121 patients
undergoing resection with curative intent in a single institution duringCardiovascular Surgery c Volume 137, Number 3 615




BAC ¼ bronchioloalveolar carcinoma
ERK ¼ extracellular signal–regulated kinase
NSCLC ¼ non–small cell lung carcinoma
VHL ¼ von Hippel–Lindau
a 12-year period. Cases were selected to ensure adequate representation of
histologic subtypes and stages. Hematoxylin and eosin–stained slides from
each primary lesion were reviewed, and the tumors were classified accord-
ing to World Health Organization guidelines.5 Staging was performed ac-
cording to the American Joint Committee on Cancer TNM system.6 The
clinicopathologic features are summarized in Tables 1 and 2. Lesions
were categorized as squamous cell carcinoma (n ¼ 20), adenocarcinoma
(n ¼ 132), or adenosquamous carcinoma (n ¼ 2); the adenocarcinomas
were further subclassified as bronchioloalveolar carcinoma (BAC) subtype
only (n ¼ 38), patterns other than BAC (ie, acinar, papillary, and solid pat-
terns; n¼ 18), or mixtures of BAC and non-BAC adenocarcinoma (n¼ 76).
Of the 154 tumors, 87 were unifocal, and the remaining 67 tumors were re-
sected from 33 patients who presented with more than 1 lesion. These 67
multifocal lesions, which theoretically include both synchronous primary
metastases, as well as intralobar satellites and pulmonary metastases,
were staged in accordance with American Joint Committee on Cancer
guidelines: multifocal lesions with identical histologic features were staged
as T4 if present within the same lobe and M1 if present within different
lobes; lesions with different histologic features or without invasion (ie,
pure BAC) were considered synchronous primary carcinomas and staged in-
dependently.6
Clinical features and outcome data were obtained from a prospectively
established thoracic surgery database. Follow-up information, including
evidence of recurrence in history and physical examination findings
and in radiology and pathology reports, was obtained from office notes
and hospital records. Median length of follow-up for adenocarcinomas
was 2.2 years (range, 3 months to 15 years). Institutional review board
permission for the study was obtained, and patient consent was waived
in accordance with the Health Insurance Portability and Accountability
Act.
Immunohistochemistry
Immunohistochemical staining was performed on 5-mm-thick, formalin-
fixed, paraffin-embedded tissue sections by using the BondMax Automated
Immunohistochemistry and In Situ Hybridization System (Leica-Vision Bi-
osystems, Melbourne, Australia) and the Bond Polymer Define peroxidase
detection system (Leica-Vision BioSystems). Anti-CXCL12 antibody
(clone 79018; R&D Systems, Minneapolis, Minn) and anti-CXCR4 anti-
body (clone 12G5, R&D Systems) were used at dilutions of 1:250 and
1:150, respectively, in Bond Primary Antibody Diluent (Leica-Vision Bio-
Systems) with 0.5% casein block after antigen retrieval with Bond Epitope
Retrieval Solution no. 1 for 30 minutes. Immunostaining was performed ac-
cording to a modified manufacturer’s protocol: incubation with the primary
antibody (25 minutes), a postprimary step (15 minutes), and a detection step
(Bond Polymer Define system, 25 minutes). The peroxidase reaction was
developed with diaminobenzidine. Sections were counterstained with he-
matoxylin, dehydrated, and embedded in Cytoseal TMXYL (Richard Allan
Scientific, Kalamazoo, Mich). Appropriate negative controls lacking pri-
mary antibody were performed.
CXCL12 staining was observed in the cytoplasm and cell membranes of
NSCLC cells but not in the nuclei. CXCR4 staining was observed in both
a nuclear and cytomembranous pattern in malignant cells, and intensity
for these 2 compartments was scored independently. Intensity was scored
as 0þ (absent), 1þ (low intensity), 2þ (intermediate), 3þ (high intensity), or616 The Journal of Thoracic and Cardiovascular Su4þ (very high intensity) individually by 2 pathologists (PLW and AS)
who were blinded to staging and outcome information. The lesions were
then jointly examined by both pathologists to resolve discrepancies in scor-
ing; there was high concordance (>90%) in the initial interpretation of
staining intensity. Tumors scoring 0þ or 1þ were categorized as having
low–absent expression, whereas those designated as 2þ, 3þor 4þwere cat-
egorized as having high-level expression. In cases with intratumoral vari-
ability in staining intensity, the predominant pattern was recorded.
Examples are provided in Figures 1 and 2.
The pathologist-assigned intensity scores were validated by using the
Applied Imaging Ariol analysis system (Genetix Ltd, New Milton, United













Mean age (y) 67  8 66  8 67  8 .6*
Sex
Male 44 19 (43) 25 (57) .05y




75 22 (29) 53 (71)
Adenocarcinoma–BAC
onlyzz
37 7 (19) 30 (81) .4z
Adenocarcinoma–non-
BACzz
18 3 (17) 15 (83)
*Adenocarcinoma–total 130 32 (25) 98 (75) .0001x
Squamous 18 14 (78) 4 (22)
Adenosquamous 2 1 1
Focality
Unifocal 84 33 (39) 51 (61) .02k
Multifocal 66 14 (21) 52 (79)
T score
T1 78 18 (23) 60 (77) .03{
T2 45 21 (47) 24 (53)
T3 1 1 0
T4 26 7 (27) 19 (73)
N score
N0 108 27 (25) 81 (75) .01#
N>0 42 20 (48) 22 (52)
M score
M0 144 44 (31) 100 (69) .5**
M1 6 3 (50) 3 (50)
Stage
I 89 20 (22) 69 (78) .007yy
II 17 9 (53) 8 (47)
III 38 15 (39) 23 (61)
IV 6 3 (50) 3 (50)
Percentages are shown in parentheses. IHC, Immunohistochemistry; BAC, bronchio-
loalveolar carcinoma. *P value corresponding to the Student t test comparing age
among strong staining versus weak–absent staining for each antibody. The remaining
P values correspond to the Fisher’s exact or c2 test comparing strong versus absent
staining for each antibody among subgroups defined as follows: ymale versus
female; zmixed versus BAC only versus non-BAC adenocarcinoma subtypes;
xadenocarcinoma (all subtypes) versus squamous carcinoma; kunifocal versus multi-
focal; {T1 versus T2 to T4; #N0 versus N1 to N2; **M0 versus M1; yystage I versus
stage II to IV. zzHistologic subtypes of adenocarcinoma, summed as ‘‘Adenocarci-
noma–total’’ for comparison with other histologic types (squamous and adenosqua-
mous).rgery c March 2009
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STABLE 2. Correlation of CXCR4 immunohistochemical staining with clinicopathologic features











(n ¼ 107) P value
Mean age (y) 67  8 67  8 66  8 .7* 66  8 68  9 .1*
Sex
Male 46 17 (37) 29 (63) .7y 15 (33) 31 (67) .7y
Female 108 45 (42) 63 (58) 32 (30) 76 (70)
Histology
Adenocarcinoma–mixed subtypexx 76 30 (39) 46 (61) 29 (38) 47 (62)
Adenocarcinoma–BAC onlyxx 38 23 (61) 15 (39) .01z 9 (24) 29 (76) .2z
Adenocarcinoma–non-BACxx 18 4 (22) 14 (78) 4 (22) 14 (78)
Adenocarcinoma–total 132 57 (43) 75 (57) .01x 42 (32) 90 (68) .1x
Squamous 20 3 (15) 17 (85) 3 (15) 17 (85)
Adenosquamous 2 2 0 2 0
Focality
Unifocal 87 28 (32) 59 (68) .02k 21 (24) 66 (76) 0.06k
Multifocal 67 34 (51) 33 (49) 26 (39) 41 (61)
T score
T1 80 40 (50) 40 (50) .01{ 24 (30) 56 (70) .4{
T2 47 14 (30) 33 (60) 13 (28) 34 (72)
T3 1 0 1 1 0
T4 26 8 (31) 18 (69) 9 (35) 17 (65)
N score
N0 110 46 (42) 64 (58) .6# 34 (31) 76 (69) 1.0#
N>0 44 16 (36) 28 (64) 13 (30) 31 (70)
M score
M0 148 58 (39) 90 (61) 0.2** 42 (28) 106 (72) .01**
M1 6 4 (67) 2 (33) 5 (83) 1 (17)
Stage
I 90 40 (44) 50 (56) .2yy 27 (30) 63 (70) .03zz
II 19 5 (26) 14 (74) 4 (21) 15 (79)
III 39 13 (33) 26 (67) 11 (28) 28 (72)
IV 6 4 (67) 2 (33) 5 (83) 1 (17)
Percentages are shown in parentheses. IHC, Immunohistochemistry; BAC, bronchioloalveolar carcinoma. *P value corresponding to the Student t test comparing age among strong
staining versus weak–absent staining for each antibody. The remaining P values correspond to the Fisher’s exact or c2 tests comparing strong versus absent staining for each an-
tibody among subgroups defined as follows: ymale versus female; zmixed versus BAC only versus non-BAC adenocarcinoma subtypes; xadenocarcinoma (all subtypes) versus
squamous carcinoma; kunifocal versus multifocal; {T1 versus T2 to T4; #N0 versus N1 to N2; **M0 versus M1; yystage I versus stage II to IV; zzstage I to III versus stage IV.
xxHistologic subtypes of adenocarcinoma, summed as ‘‘Adenocarcinoma–total’’ for comparison with other histologic types (squamous and adenosquamous).Kingdom).7,8 This high-throughput image analysis system was used to yield
high-resolution numeric intensity scores for cytomembranous and nuclear
staining with CXCR4 and CXCL12 on a tissue microarray constructed
from the tumors analyzed in this study. The numeric scores, generated on
a scale from 1 to 255, were tested for correlation with the pathologist-as-
signed intensity scores for each antibody on each tumor by using Spear-
man’s rank coefficient test. Excellent overall agreement between the
automated system and the pathologists’ assessment was demonstrated for
each antibody as follows: CXCL12 cytomembranous staining (rs ¼ 0.5,
P < .0001), CXCR4 cytomembranous staining (rs ¼ 0.21, P ¼ .02),
CXCR4 nuclear staining (rs ¼ 0.36, P ¼ .0002).
Statistical Analysis
The clinicopathologic and immunohistochemical features of the lesions
were evaluated with either an unpaired Student t test or the Fisher’s exact
test, as appropriate. DFS curves were generated by using the Kaplan–Meier
method (Prism 5; GraphPad Software, Inc, San Diego, Calif) and compared
with the log-rank and Wilcoxon tests. A multivariate Cox proportional haz-
ards regression model of independent prognostic factors for DFS was per-
formed (SPSS, Inc, Chicago, Ill).The Journal of Thoracic andRESULTS
Association of CXCL12 Expression With
Clinicopathologic Features and Outcome
CXCL12 immunostaining demonstrated a cytoplasmic
and membranous distribution and was present to some extent
in nearly every lesion, as well as in adjacent normal bronchial
and alveolar epithelial cells. Sufficient material was available
for CXCL12 immunostaining of 150 of the 154 primary
NSCLC lesions (Figure 1 and Table 1), which were catego-
rized as expressing high levels of CXCL12 (n ¼ 47) or
low–absent levels of CXCL12 (n ¼ 103). Male patients
tended to exhibit increased CXCL12 staining relative to fe-
male patients (43% vs 26%, P¼ .05). Squamous cell carci-
nomas (14/18 [78%]) were more likely to express high-level
CXCL12 than adenocarcinomas (32/132 [25%], P< .01),
whereas unifocal tumors (33/84 [39%]) more frequently
expressed high-level CXCL12 than multifocal lesionsCardiovascular Surgery c Volume 137, Number 3 617
General Thoracic Surgery Wagner et al
G
T
SFIGURE 1. Immunohistochemical staining for CXCL12. A, Malignant cells exhibit low–absent CXCL12 reactivity compared with adjacent bronchial
epithelium (upper right) and alveolar pneumocytes (lower right). B, Malignant cells in the right half of the image exhibit strong cytomembranous staining
relative to the nonneoplastic pneumocytes in the left half of the image. C, Negative control lacking primary antibody; for comparison, the inset shows same
area stained with CXCL12 primary antibody. Scale bars ¼ 100 mm.(14/66 [21%], P ¼ .02). Low–absent CXCL12 expression
was associated with a lower T classification: 58% of these le-
sions were T1 compared with 38% of lesions expressing
high levels of CXCL12 (P ¼ .02). Likewise, node-negative
lesions expressed lower levels of CXCL12 compared with
tumors with positive lymph nodes (75% vs 52%, P ¼
.01), and we observed a corresponding association of low-
level CXCL12 expression with stage I disease (Table 1, P
¼ .007). Despite the association of CXCL12 levels with dif-
ferences in node status and stage, DFS did not significantly
differ between lesions with high-level CXCL12 expression
and those with low-level expression (Figure 3, D).
Association of CXCR4 Expression With
Clinicopathologic Features and Outcome
Nuclear and cytomembranous CXCR4 immunostaining
were scored separately (Figure 2) in all 154 primaryNSCLCs. High-intensity nuclear and cytomembranous
staining was present in 62 (40%) of 154 and 47 (31%) of
154 lesions, respectively. Nuclear CXCR4 expression ex-
hibited significant associations in univariate analysis with
respect to histologic type of NSCLC, multifocality, T classi-
fication, and DFS (Table 2). Regarding histotype, squamous
cell carcinomas were less likely than adenocarcinomas to ex-
press high-level nuclear CXCR4 (15% vs 43%, P ¼ .01),
whereas among subtypes of adenocarcinoma, lesions con-
taining only BAC were more likely to express high-level nu-
clear CXCR4 than lesions exhibiting patterns other than
BAC (61% vs 36%, P ¼ .01). High-level nuclear staining
was associated with multifocality: 51% of multifocal lesions
showed high-level nuclear CXCR4 compared with 32% of
unifocal lesions (P ¼ .02). Lesions with high-level nuclear
CXCR4 staining were more likely to be T1 than those
with low–absent nuclear CXCR4 (P ¼ .01). No significantFIGURE 2. Immunohistochemical staining for CXCR4. A, Malignant cells in the lower half of the image exhibit low–absent nuclear and cytomembranous
CXCR4 staining; note the strong staining of adjacent lymphocyte nuclei in the upper portion of image. B, Malignant cells in the center of the panel exhibit
strong nuclear and low–absent cytomembranous staining; note interspersed CXCR4þ lymphocytes. C, Malignant cells exhibit strong nuclear and cytomem-
branous CXCR4 reactivity. D, Negative control lacking primary antibody; for comparison, the inset shows the same area stained with CXCR4 primary an-
tibody. Scale bars ¼ 100 mm.
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SFIGURE 3. Disease-free survival (DFS) among adenocarcinomas with respect to CXCL12 and CXCR4 immunohistochemical staining. A, Association
of cytomembranous CXCR4 with decreased DFS. B, Association of nuclear CXCR4 with increased DFS. C, Particularly favorable prognosis for lesions with
the combination of high nuclear and low cytomembranous CXCR4 levels. D, Lack of significant association of CXCL12 with DFS. Numerals represent the
number at risk at 1, 3, and 5 years.association between nuclear CXCR4 expression and N or M
classification was noted. High-level nuclear CXCR4 was as-
sociated with improved DFS relative to low–absent nuclear
expression (P ¼ .02; Figure 3, B).
Among the clinicopathologic features studied, cytomem-
branous CXCR4 staining was significantly associated only
with distant metastases and DFS: M1 (stage IV) lesions
were more likely to exhibit high-level cytomembranous
CXCR4 staining than were M0 lesions (83% vs 28%,
P ¼ .01), and high-level cytomembranous CXCR4 expres-
sion was associated with a poorer prognosis among adeno-
carcinomas (P ¼ .04; Figure 3, A).
As stated above, nuclear high-level CXCR4 expression
was associated with a better prognosis, whereas cytomem-
branous CXCR4 expression was associated with a poorer
prognosis. The combination of strong nuclear CXCR4 pos-
itivity and weak–absent cytomembranous staining was asso-
ciated with a particularly favorable prognosis (hazard ratio,
0.38; 95% confidence interval [CI], 0.16–0.87; P ¼ .02).
To determine whether CXCR4 immunostaining carries inde-
pendent prognostic implications, we conducted Cox multi-
variate proportional hazard ratio regression analysis.
Univariate analysis identified a significant association of
DFS with unifocality (P ¼ .02), negative lymph node status
(P ¼ .049), high-level nuclear CXCR4 staining (P ¼ .047),The Journal of Thoracic and Cand low-level cytomembranous CXCR4 staining (P ¼ .02).
In multivariate analysis incorporating staging parameters,
nuclear CXCR4 staining was significantly associated with
improved DFS, with a relative risk of death or recurrence
of 0.38 (95% CI, 0.17–0.89, P ¼ .03), whereas cytomem-
branous CXCR4 staining was significantly associated with
decreased DFS (relative risk, 2.8; 95% CI, 1.4–5.7; P ¼
.004), indicating that the observed effects are stage inde-
pendent.
DISCUSSION
Chemokine receptors, in addition to their physiologic
roles in development and immunity, play an increasingly
recognized role in the progression of numerous human
malignancies. Tumor cells expressing these receptors can re-
spond to chemokines by undergoing increased proliferation,
angiogenesis, and invasion. Moreover, because of the spe-
cific nature of the chemokine ligand–receptor interaction,
metastasis could occur in a site-specific manner determined
by the specific chemokine receptors expressed by circulating
tumor cells and the subset of chemokines that are constitu-
tively secreted by any given target organ.1 The chemokine
CXCL12 is expressed in common sites of metastasis, includ-
ing lymph nodes, lungs, liver, and bone marrow, and in an-
imal models the interaction between CXCL12 generated byardiovascular Surgery c Volume 137, Number 3 619
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and lung carcinoma cells has been demonstrated to be a vital
step in the establishment of metastatic lesions in these
sites.2,3 However, the clinical relevance of this interaction
is poorly defined in NSCLC, and the purpose of this study
was to assess whether CXCL12 and CXCR4 are associated
with tumor progression and survival.
We found that these molecules are indeed associated with
significant differences in clinicopathologic features among
NSCLCs. On univariate analysis, we determined that
CXCL12 expression is associated with nodal metastasis
but has no measurable effect on DFS. CXCR4, when present
in the nucleus, is associated with multifocality and lower T
classification, whereas cytomembranous CXCR4 expres-
sion is linked with stage IV disease. Likewise, multivariate
analysis revealed an independent association of CXCR4
with survival depending on its subcellular location, with nu-
clear staining correlating with favorable prognosis and cyto-
membranous staining correlating with poorer prognosis.
Thus localization of CXCR4 within the nucleus of NSCLC
cells appears to have an overall inhibitory effect on tumor
progression, whereas cytomembranous CXCR4 is an inde-
pendent risk factor for poor outcome.
CXCR4 expression in NSCLC has been established to
play a role in tumor progression and metastasis in vitro
and in murine models.3,9 Two studies have attempted to
determine the clinical significance of these findings. Spano
and colleagues,10 studying only stage I lesions, found an
association between nuclear CXCR4 staining and in-
creased survival among 61 patients. Because of their inclu-
sion criteria, node-positive versus node-negative lesions
could not be compared nor could T classification, multifo-
cality, or stage. Su and associates9 observed high-level cy-
tomembranous CXCR4 staining in 17 of 34 patients and
noted a significant correlation between high cytomembra-
nous CXCR4 staining intensity and metastasis in univari-
ate analysis. However, interpretation of their data is
restricted by the fact that lymph node, regional, and distant
metastatic lesions were included as one group and impor-
tant staging information was not provided, preventing
assessment of the independent effects of CXCR4 expres-
sion on survival. By incorporating clinicopathologic
features of 154 primary NSCLCs with outcome data in
a multivariate analysis, our report is the first to establish
CXCR4 expression as an independent prognostic indicator
in NSCLC.
Regulation of CXCL12 and CXCR4 expression is incom-
pletely understood. Both genes are negatively regulated by
the von Hippel–Lindau (VHL) tumor suppressor protein,
an effect that is removed under hypoxic conditions or be-
cause of inactivation of the VHL gene, which occurs fre-
quently in NSCLC.11,12 Because loss of VHL leads to
increased production of both receptor (CXCR4) and ligand
(CXCL12) within the same cell, the result is an autocrine620 The Journal of Thoracic and Cardiovascular Sustimulus for proliferation and metastasis, as previously de-
scribed in NSCLC, hemangioblastoma, and renal cell carci-
noma cell lines.13,14 Likewise, adjacent nonneoplastic
bronchial and alveolar epithelial cells could also stimulate
tumor progression in a paracrine fashion by secreting
CXCL12.3,15 CXCR4 has also been shown to be upregu-
lated in response to epidermal-derived growth factor in
NSCLC and RET-derived oncogenes in papillary thyroid
carcinoma, whereas epigenetic mechanisms are known to in-
fluence CXCL12 expression in carcinoma of the colon and
breast.13,16-18 Further studies will be necessary to distinguish
whether these mechanism, characterized in cell lines, are
also important in upregulating CXCR4 and CXCL12 ex-
pression in vivo.
The downstream intracellular effects of stimulation of
CXCR4 by CXCL12 have been well characterized. Binding
of CXCL12 to CXCR4 results in receptor dimerization and
endosomal internalization of the receptor–ligand complex.
Once in the cell, CXCR4 maintains a close physical associa-
tion with extracellular signal–regulated kinases (ERKs) and
cyclophilin A in the vicinity of the nuclear membrane, where
it participates in phosphorylation and nuclear translocation of
ERK1/2, a downstream mediator of epidermal-derived
growth factor signaling.19-21 The observation that nuclear lo-
calization of CXCR4 confers a prognostic benefit in NSCLC
raises the possibility that CXCR4 might have an as-yet-
undiscovered direct activity within the nucleus, perhaps
related to ERK1/2 translocation, that inhibits tumor progres-
sion. Alternatively, Spano and colleagues10 proposed that se-
questration of CXCR4 within the nucleus could prevent this
receptor from exerting its tumor-promoting effects in the cy-
toplasm or cell membrane. Future experimentation will be re-
quired to address the mechanisms of nuclear localization and
potential intranuclear activity of CXCR4. Interestingly,
a similar association of nuclear CXCR4 expression with im-
proved survival and cytomembranous expression with worse
prognosis has recently been reported in breast carcinoma,22
suggesting the existence of a shared mechanism of CXCR4
activity in common epithelial malignancies.
Additional effects of the CXCL12–CXCR4 interaction in
malignant cells include calcium mobilization and activation
of Ras/Raf, mitogen-activated protein kinases, Phosphoino-
sitide 3-Kinase (PI3), and Akt.3,19 Ultimately, stimulated
cells undergo cytoskeletal rearrangement and altered tran-
scription to assume a phenotype of increased proliferation,
resistance to apoptosis, and enhanced migration and inva-
sion of extracellular matrix.3,17 Presumably, the intracellular
response of CXCR4-expressing tumor cells to CXCL12 ac-
counts for the observed association of these molecules with
indicators of tumor aggressiveness and progression, such as
higher T classification, nodal and distant metastasis, and de-
creased DFS.
In summary, the chemokine receptor CXCR4 is associ-
ated with indicators of tumor progression and independentlyrgery c March 2009
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Spredicts decreased DFS when present in the cytoplasm and
cell membrane of NSCLC cells. Cytomembranous expres-
sion of CXCR4 could thus define a subset of patients with
lung cancer who might benefit from small peptide inhibitors
of CXCR4 currently under investigation.23,24 Further studies
are necessary to discern the mechanisms and significance of
nuclear localization of CXCR4, which appears to be associ-
ated with lower tumor stage and increased survival in lung
and breast carcinoma.
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